Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip J Stephens

Showing results (131-140 of 168) with videos related to

Pageof 17
Sort By:
Molecular Cancer Therapeutics|March 11, 2014
Concordance of genomic alterations between primary and recurrent breast cancerFunda Meric-Bernstam, Garrett M Frampton, Jaime Ferrer-Lozano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2022
Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell CarcinomaChristine H Chung, Jiannong Li, Conor E Steuer, et al.
Science Translational Medicine|July 2, 2010
Genomic architecture characterizes tumor progression paths and fate in breast cancer patientsHege G Russnes, Hans Kristian Moen Vollan, Ole Christian Lingjærde, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 20, 2017
Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic ProfilingAlexa B Schrock, Shuyu D Li, Garrett M Frampton, et al.
Cancer Discovery|September 16, 2015
RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 InhibitorsHaiying Cheng, Yiyu Zou, Jeffrey S Ross, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 7, 2013
A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinomaJeffrey S Ross, Kai Wang, Laurie M Gay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2016
Comprehensive Genomic Profiling Identifies Frequent Drug-Sensitive EGFR Exon 19 Deletions in NSCLC not Identified by Prior Molecular TestingAlexa B Schrock, Garrett M Frampton, Dana Herndon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2018
Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung CancerJessica J Lin, Viola W Zhu, Satoshi Yoda, et al.
Journal of the National Cancer Institute|December 11, 2014
Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studiesMatthew P Goetz, James X Sun, Vera J Suman, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 18, 2014
Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasmsRaajit Rampal, Jihae Ahn, Omar Abdel-Wahab, et al.
Pageof 17

Showing results (131-140 of 168) with videos related to

Sort By:
Pageof 17
Molecular Cancer Therapeutics|March 11, 2014
Concordance of genomic alterations between primary and recurrent breast cancerFunda Meric-Bernstam, Garrett M Frampton, Jaime Ferrer-Lozano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2022
Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell CarcinomaChristine H Chung, Jiannong Li, Conor E Steuer, et al.
Science Translational Medicine|July 2, 2010
Genomic architecture characterizes tumor progression paths and fate in breast cancer patientsHege G Russnes, Hans Kristian Moen Vollan, Ole Christian Lingjærde, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 20, 2017
Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic ProfilingAlexa B Schrock, Shuyu D Li, Garrett M Frampton, et al.
Cancer Discovery|September 16, 2015
RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 InhibitorsHaiying Cheng, Yiyu Zou, Jeffrey S Ross, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 7, 2013
A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinomaJeffrey S Ross, Kai Wang, Laurie M Gay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2016
Comprehensive Genomic Profiling Identifies Frequent Drug-Sensitive EGFR Exon 19 Deletions in NSCLC not Identified by Prior Molecular TestingAlexa B Schrock, Garrett M Frampton, Dana Herndon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2018
Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung CancerJessica J Lin, Viola W Zhu, Satoshi Yoda, et al.
Journal of the National Cancer Institute|December 11, 2014
Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studiesMatthew P Goetz, James X Sun, Vera J Suman, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 18, 2014
Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasmsRaajit Rampal, Jihae Ahn, Omar Abdel-Wahab, et al.
Pageof 17